Back to top
more

Novavax (NVAX)

(Delayed Data from NSDQ)

$11.99 USD

11.99
4,400,799

+0.03 (0.25%)

Updated Aug 23, 2024 03:59 PM ET

After-Market: $11.96 -0.03 (-0.25%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Endo (ENDP) Q3 Earnings & Sales Top Estimates, View Raised

Endo's (ENDP) earnings and sales beat estimates in the third quarter. The company raises its annual outlook.

Novavax (NVAX) to Report Q3 Results: Wall Street Expects Earnings Growth

Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Can Coronavirus Vaccine Efforts Aid Novavax (NVAX) Q3 Earnings?

During Novavax's (NVAX) upcoming third-quarter earnings call, investor focus will be on the company's progress with its COVID-19 vaccine candidate NVX-CoV2373.

Biotech Stock Roundup: GILD's Veklury Approved, NVAX Provides Vaccine Update & More

Gilead (GILD) and Novavax (NVAX) continue to be in the spotlight on coronavirus-related updates.

Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know

Novavax (NVAX) closed at $93.13 in the latest trading session, marking a -0.49% move from the prior day.

Endo (ENDP) Gains on Deal to Acquire BioSpecifics for $540M

Endo (ENDP) gains from the acquisition of commercial-stage biopharmaceutical company, BioSpecifics Technologies Corp.

Novavax (NVAX) Dips More Than Broader Markets: What You Should Know

Novavax (NVAX) closed at $111.42 in the latest trading session, marking a -0.3% move from the prior day.

Vaxart (VXRT) Begins Dosing in Oral Coronavirus Vaccine Study

Vaxart (VXRT) doses the first subject in an early-stage study of its oral coronavirus vaccine candidate VXA-CoV2-1. Stock rises.

Novavax (NVAX) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Novavax (NVAX) closed at $111.02, marking a +0.93% move from the previous day.

Mark Vickery headshot

Small-Caps, Energy Win the Trading Day

The Energy sector was one of the biggest winners on the day, coming after weeks of hard-hit commodity prices finally getting a little traction.

Biotech Stock Roundup: REGN's Cocktail Data, GILD's RA Drug Approval & Other Updates

The biotech sector remains in focus with regulatory and other pipeline updates.

Novavax (NVAX) Gains But Lags Market: What You Should Know

Novavax (NVAX) closed at $108.35 in the latest trading session, marking a +0.37% move from the prior day.

CureVac Begins Phase IIa Study on Coronavirus Vaccine Candidate

CureVac (CVAC) doses the first patient in a phase IIa study on its COVID-19 vaccine candidate CVnCoV. Shares rise in after-hours trading following this development.

Endo Up on COVID-19 Vaccine Manufacturing Deal with Novavax

Endo (ENDP) and Novavax enter a manufacturing agreement for the latter's COVID-19 vaccine candidate, NVX-CoV2373.

Company News for Sep 28, 2020

Companies In The News Are: TCOM, BA, NVAX, HON.

Keysight, Mesa, Costco and Novavax as Zacks Bull and Bear of the Day

Keysight, Mesa, Costco and Novavax as Zacks Bull and Bear of the Day

Novavax Begins Phase III Study on Coronavirus Vaccine in the UK

Novavax (NVAX) starts a phase III efficacy study on its COVID-19 vaccine candidate NVX-CoV2373 in the United Kingdom. Stock rises in after-hours trading.

Mark Vickery headshot

Rollercoaster Market for Thursday

The major indexes gained less than 1% in total Thursday: +0.37% on the Nasdaq, +0.30% on the S&P 500, +0.20% on the Dow and +0.02% for the Russell 2000.

The Zacks Analyst Blog Highlights: NVAX, MRNA, VIR and BNTX

The Zacks Analyst Blog Highlights: NVAX, MRNA, VIR and BNTX

Kinjel Shah headshot

4 Biotechs That Have More Than Doubled Thanks to Coronavirus

Stocks of several small biotech companies more than double so far this year as they taste success in their efforts to make a vaccine/medicine for treating COVID-19.

Novavax (NVAX) Gains As Market Dips: What You Should Know

Novavax (NVAX) closed the most recent trading day at $110.15, moving +1.65% from the previous trading session.

Novavax Expands Coronavirus Vaccine Manufacturing Deal in India

Novavax (NVAX) amends its present contract with Serum Institute of India Private Limited to widen the manufacturing capacity of its COVID-19 vaccine candidate NVX-CoV2373 to 2 billion plus doses in 2021.

Vaxart Gets FDA Nod for Phase I Study on Coronavirus Vaccine

Vaxart's (VXRT) investigational new drug application for oral coronavirus vaccine candidate gets a clearance from the FDA. The company will begin a phase I study later this month.

Why Is Novavax (NVAX) Down 42.9% Since Last Earnings Report?

Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Kinjel Shah headshot

Coronavirus Vaccine Efforts Hit as AstraZeneca Halts Study

Amid rising optimism on timely approval of a safe vaccine, the vaccine development efforts of AstraZeneca (AZN) have hit a roadblock.